The Indiana University Philanthropic Venture Fund has invested $200,000 in Carmel-based Confluence Pharmaceuticals to treat autism-related impairments. The company’s Chief Executive Officer Steve Johns said a product for the treatment to improve patients’ communication, social interaction and self-care is underway.
Confluence Pharmaceuticals will use the investment to accelerate clinical development and regulatory activities.
Confluence Pharmaceuticals develops what it describes as novel, clinically discovered, therapeutic treatments for core social and communication impairments related to fragile X syndrome and autism spectrum disorder.
"Today, no medication exists to treat these core impairments," Johns said. "Early pilot studies have demonstrated the potential of our product to improve focus, communication, social withdrawal and attention deficit hyperactivity disorder."